Ocugen's Amsterdam Office Opens as CEO Sale Notice Lands Before Key Capital Vote
Published on 10/12/2026 at 15:10 | Editorial boerse-global.de
Ocugen has picked Jolanda Crombach to run its Dutch subsidiary in Amsterdam, a hire that puts the U.S. biotech's late-stage clinical programs under European leadership while the company still waits on the data that would justify the buildout. Crombach will serve as General Manager of the Netherlands entity, guiding the Phase 3 trials for OCU400, OCU410 and OCU410ST and laying groundwork for a possible commercial launch across the continent. The appointment was made last Tuesday.
That organizational move lands well ahead of the science it is meant to support. Ocugen's management has pointed to pivotal readouts from those studies arriving in 2027 and 2028, leaving a long stretch in which regulatory groundwork and distribution planning must proceed without product revenue behind them.
A Balance Sheet Still Deep in the Red
The cost of standing up international operations shows up plainly in the second-quarter 2026 figures. Ocugen booked revenue of $1.49 million for the three-month period, against operating expenses of $17.9 million — up from $15.2 million in the same quarter of 2025. The GAAP net loss came to $24.88 million.
Late-stage trials and the preparation of new market regions keep draining cash at this stage of development, which makes the durability of the company's financial base the central question for investors.
Should investors sell immediately? Or is it worth buying Ocugen?
To bridge the gap until those hoped-for data points arrive later in the decade, management points to $130 million in convertible note financing. According to the company, that funding extends its financial runway into 2028. Even so, Ocugen needs more room on its balance sheet, which is why shareholders are being asked to reconvene.
October 26 Vote Set After a Week of Delay
The adjourned shareholder meeting is now scheduled for October 26, 2026, at 8:00 a.m. local time. On the agenda is a proposal to expand authorized common stock by 250,000,000 shares. The resolution was postponed roughly a week ago, and the stock has slipped 9.1% since that delay.
Market caution reflects the sector's familiar tension: ambitious pipeline targets running up against concrete dilution and financing pressure. Year to date, the shares are down 32%, with the stock recently at EUR 0.8470. The most recent session closed at EUR 0.8530, a decline of 2.6% on the day, for which no direct company-specific explanation was available.
CEO's Prearranged Sale Adds to the Overhang
Shankar Musunuri, Ocugen's chief executive, filed a Form 144 notice on Friday signaling an intent to sell 525,991 common shares, with a proposed sale date of October 9. The transaction traces back to a Rule 10b5-1 trading plan the chairman established on June 5, 2026 — a mechanism that lets U.S. corporate officers automate securities sales under pre-set criteria. The Form 144 filing declares an intention to sell and does not by itself confirm that the trade has been executed.
Against that backdrop, attention now centers on how the meeting at the end of the month plays out. Only once shareholders rule on the proposed share issuance will it be clear how much latitude management has for future fundraising.
Pipeline Progress Continues in the Meantime
Research momentum, meanwhile, remains the foundation any eventual commercialization would rest on. Ocugen presented two talks covering twelve-month results from the ArMaDa study of OCU410 in geographic atrophy. Turning such interim clinical findings into approved therapies, however, will demand considerable patience from shareholders.
Ad
Ocugen Stock: New Analysis - 12 October
Fresh Ocugen information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
